Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JS1K | ISIN: IE00B4Q5ZN47 | Ticker-Symbol: J7Z
Tradegate
21.11.24
11:57 Uhr
116,00 Euro
+2,80
+2,47 %
1-Jahres-Chart
JAZZ PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
JAZZ PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
113,00118,0012:30
113,00118,0011:57

Aktuelle News zur JAZZ PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11:06Jazz Pharmaceuticals plc - 8-K, Current Report-
02:34Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment1
JAZZ PHARMACEUTICALS Aktie jetzt für 0€ handeln
01:59Jazz Pharma Gains FDA Accelerated Approval For Ziihera To Treat HER2-positive Biliary Tract Cancer1
01:19Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract ...16Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response...
► Artikel lesen
DiJazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference194DUBLIN, Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management...
► Artikel lesen
SaKBC Group NV Has $25.44 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)6
13.11.Jazz Pharmaceuticals' EVP Neena Patil verkauft Aktien im Wert von 456.617 US-Dollar7
07.11.Jazz Pharmaceuticals plc - 10-Q, Quarterly Report10
07.11.Jazz Pharmaceuticals PLC reports results for the quarter ended in September 30 - Earnings Summary7
07.11.Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?15
06.11.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results193- 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and Rylaze® -- 2024 total revenue guidance affirmed at $4.0 to $4.1 billion -- Zanidatamab 2L BTC...
► Artikel lesen
06.11.Jazz Pharmaceuticals plc - 8-K, Current Report-
06.11.Insider Decision: Bruce C Cozadd Offloads $110K Worth Of Jazz Pharmaceuticals Stock9
05.11.CEO von Jazz Pharmaceuticals, Bruce Cozadd, verkauft Aktien im Wert von 110.840 US-Dollar8
27.10.Jazz Pharmaceuticals plc (JAZZ): Among the Best Stocks to Buy for High Returns in 20246
23.10.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024294DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024,...
► Artikel lesen
23.10.In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals7
23.10.RBC lifts Jazz Pharmaceuticals stock target on zanidatamab outlook5
16.10.Jazz Pharmaceuticals kündigt Mietvertrag für 20255
16.10.Jazz Pharmaceuticals to terminate lease in 20251
Seite:  Weiter >>
102 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1